ArticleCureus2026
Seizure Mimics as the Presenting Feature of a Functional Metastatic Pancreatic Neuroendocrine Tumour in a Patient With Pre-existing Epilepsy: A Diagnostic Challenge.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulinomas and functional pancreatic neuroendocrine tumours (pNETs) are rare but important causes of endogenous hyperinsulinaemic hypoglycaemia whose neuroglycopenic manifestations can closely mimic neurological disorders, leading to considerable diagnostic delay. We present the case of a 74-year-old man with epilepsy, seizure-free for 11 years on carbamazepine, and a background of metastatic well-differentiated grade 3 pNET (Ki-67: 40-50%), who was admitted with a 2-3-week history of nocturnal confusion, cold sweats, nightmares, increasing agitation, and an episode of abnormal limb movements. The presentation was initially attributed to possible seizure recurrence or delirium. Routine investigations, including CT brain, carbamazepine levels, and type 1 antineuronal nuclear autoantibody antibody testing, were unremarkable, and blood glucose on admission was normal. The correct diagnosis was reached only during a witnessed ward episode on day two, when capillary blood glucose was found to be critically low and symptoms resolved immediately with intravenous dextrose. Subsequent biochemical evaluation demonstrated markedly elevated serum insulin (42 µU/L; reference: 2-24 µU/L), C-peptide (2,464 pmol/L; reference: <90 pmol/L), and on formal supervised 72-hour fast, which provoked symptomatic hypoglycaemia after just three hours, insulin was 180 µU/L, proinsulin was 730 pmol/L (reference: <10 pmol/L), and C-peptide was 2,136 pmol/L, with a negative sulphonylurea screen, fulfilling the diagnostic criteria for endogenous hyperinsulinaemia. Somatostatin receptor scintigraphy (single-photon emission computed tomography-computed tomography) identified multifocal hepatic metastases and focal uptake in the pancreatic tail, confirming an insulin-secreting primary. The patient was managed with diazoxide and monthly lanreotide but experienced rapid deterioration and died on palliative care. This case underscores the need to consider a functional pNET as a cause of seizure-like episodes even in patients with established epilepsy, and highlights that capillary blood glucose measurement during any witnessed neurological episode is a simple but potentially life-saving clinical step that should never be omitted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.